Samsara Vision Launches IPO on Nasdaq, Aiming to Raise $25 Million for Retinal Disease Implants

Gelonghui January 21st ┃ Samsara Vision (SMSA.US) is set to debut on Nasdaq tonight, with a price range of $5-7 per share, issuing 4.2 million shares to raise $25 million. Founded in 2015, formerly known as VisionCare Inc., Samsara Vision is headquartered in New Jersey, USA. It is a professional medical device company dedicated to bringing vision and freedom to patients suffering from advanced retinal diseases by producing medical implants for retinal conditions such as AMD. Currently, the company’s product portfolio consists of two implantable miniature telescopes (IMT) and its Tsert delivery system. In the first nine months of 2021, its revenue was $39,000, with a net loss of $5.832 million.